单纯疱疹病毒
生物
肌球蛋白
受体
细胞培养
疱疹病毒糖蛋白B
病毒进入
病毒学
病毒
分子生物学
细胞生物学
病毒复制
生物化学
遗传学
作者
Jun Arii,Hideo Goto,Tadahiro Suenaga,Masaaki Oyama,Hiroko Kozuka‐Hata,Takahiko Imai,Atsuko Minowa,Hiroomi Akashi,Hisashi Arase,Yoshihiro Kawaoka,Yasushi Kawaguchi
出处
期刊:Nature
[Nature Portfolio]
日期:2010-10-01
卷期号:467 (7317): 859-862
被引量:236
摘要
Herpes simplex virus-1 (HSV-1), the prototype of the α-herpesvirus family, causes life-long infections in humans. Although generally associated with various mucocutaneous diseases, HSV-1 is also involved in lethal encephalitis. HSV-1 entry into host cells requires cellular receptors for both envelope glycoproteins B (gB) and D (gD). However, the gB receptors responsible for its broad host range in vitro and infection of critical targets in vivo remain unknown. Here we show that non-muscle myosin heavy chain IIA (NMHC-IIA), a subunit of non-muscle myosin IIA (NM-IIA), functions as an HSV-1 entry receptor by interacting with gB. A cell line that is relatively resistant to HSV-1 infection became highly susceptible to infection by this virus when NMHC-IIA was overexpressed. Antibody to NMHC-IIA blocked HSV-1 infection in naturally permissive target cells. Furthermore, knockdown of NMHC-IIA in the permissive cells inhibited HSV-1 infection as well as cell-cell fusion when gB, gD, gH and gL were coexpressed. Cell-surface expression of NMHC-IIA was markedly and rapidly induced during the initiation of HSV-1 entry. A specific inhibitor of myosin light chain kinase, which regulates NM-IIA by phosphorylation, reduced the redistribution of NMHC-IIA as well as HSV-1 infection in cell culture and in a murine model for herpes stromal keratitis. NMHC-IIA is ubiquitously expressed in various human tissues and cell types and, therefore, is implicated as a functional gB receptor that mediates broad HSV-1 infectivity both in vitro and in vivo. The identification of NMHC-IIA as an HSV-1 entry receptor and the involvement of NM-IIA regulation in HSV-1 infection provide an insight into HSV-1 entry and identify new targets for antiviral drug development.
科研通智能强力驱动
Strongly Powered by AbleSci AI